MENU
+Compare
LENZ
Stock ticker: NASDAQ
AS OF
Dec 24 closing price
Price
$17.14
Change
+$0.25 (+1.48%)
Capitalization
536.31M

LENZ stock forecast, quote, news & analysis

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products... Show more

LENZ
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for LENZ with price predictions
Dec 23, 2025

LENZ's RSI Indicator sits in oversold zone for 7 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LENZ advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .

LENZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LENZ as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LENZ turned negative on December 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for LENZ moved below the 200-day moving average on December 15, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LENZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for LENZ entered a downward trend on December 23, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.765) is normal, around the industry mean (26.864). P/E Ratio (48.030) is within average values for comparable stocks, (51.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.882). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (27.322) is also within normal values, averaging (312.120).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LENZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LENZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 58 to 117.47B. VRTX holds the highest valuation in this group at 117.47B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 56%. BMNDF experienced the highest price growth at 467%, while VTGN experienced the biggest fall at -84%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was -16% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 54
SMR Rating: 92
Profit Risk Rating: 93
Seasonality Score: 16 (-100 ... +100)
View a ticker or compare two or three
LENZ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
445 Marine View Avenue
Phone
+1 858 925-7000
Employees
N/A
Web
https://www.lenz-tx.com